CYP1A2 and Coma: A study of 48 TRS patients (Ortega-Vázquez et al., 2021) found that drinkers carrying the CYP1A2*1C/*1C genotype had significantly higher risk of adverse reactions (OR = 7.9, p = 0.016), particularly CNS effects such as somnolence, consistent with this case.